337 F. Supp. 3d 435
D.N.J.2018Background
- End-Payor Plaintiffs (EPPs) are insurers, Taft-Hartley funds, municipalities and one individual who paid for Effexor XR or its generic; they allege Wyeth and Teva conspired to delay generic entry and keep prices supracompetitive.
- Core factual allegations: Wyeth obtained three related method-of-use patents (’171, ’958, ’120) through fraudulent nondisclosures to the PTO; Wyeth listed them in the FDA Orange Book and brought sham suits against generics; Wyeth settled with Teva in a reverse-payment agreement that delayed generic Effexor XR entry.
- EPPs sue under multiple state antitrust and consumer-protection statutes (claims across many states; class action asserted). Direct-purchaser claims under federal law are not at issue here.
- Defendants moved for judgment on the pleadings invoking: federal patent preemption, statutes of limitations, state pre-filing-notice requirements, prohibitions on class suits under some state statutes, Illinois Brick standing limits, state standing/concerted-action requirements, and sufficiency of consumer-protection pleadings.
- The Court denied preemption and statute-of-limitations dismissals; applied the continuing-violation doctrine to toll timeliness; dismissed or allowed amendment for various state claims based on notice, class-action bars, Illinois Brick repealer timing, Article III/state standing, and whether certain state statutes require concerted action or limit relief.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Federal patent preemption of state antitrust/consumer claims | EPPs: claims are antitrust/consumer-protection based and include additional elements beyond patent law, so not preempted | Wyeth/Teva: claims necessarily require adjudication of patent validity/enforceability and thus are preempted by federal patent law | Denied — state claims not preempted; applying Lipitor and Dow, state causes include additional, non-patent elements so preemption inappropriate at pleading stage |
| Timeliness (statutes of limitations) | EPPs: continuing-violation doctrine — each overpriced sale restarts limitations clock through July 2010 | Defendants: several state claims are time-barred (statutes ≤4 years) | Denied — continuing-violation applies; claims timely filed in 2011 for overcharges through July 2010 |
| State pre-filing notice & class-action bars (Shady Grove conflict) | EPPs: Federal Rule 23 should govern and preempt conflicting state notice/class restrictions | Defendants: state statutes require notice; Tennessee (and some states) bar class actions — so federal court must apply them | Mixed: state notice requirements (AZ, NV, UT antitrust; MA, WV consumer statutes) and Tennessee class-action bar apply in federal court (dismissed without prejudice); Maine notice is nonjurisdictional (claim survives) |
| Illinois Brick / state standing & scope (including DC, RI, IL, UT) | EPPs: may bring indirect-purchaser claims under state law; some repealers apply | Defendants: Illinois & some states bar indirect-purchaser class suits; DC claims lack Article III standing; Rhode Island repealer not retroactive; Utah requires resident named plaintiff | Court dismissed Illinois and Rhode Island antitrust claims with prejudice (Illinois class ban and Rhode Island repealer pre- enactment); DC claim dismissed without prejudice for lack of Article III standing; Utah claim dismissed without prejudice (need a Utah-named plaintiff) |
| State-law elements and sufficiency of consumer-protection claims | EPPs: allegations of fraud, sham litigation, reverse payment and overcharges satisfy state consumer statutes | Defendants: various states require reliance, consumer nexus, or prohibit relief for mere price-overcharge | Mixed: claims survive in CA, NV, NM, NY, NC; Illinois and Maine consumer claims dismissed with prejudice (futility); Rhode Island consumer claims dismissed with leave to amend because private recovery limited to natural-person consumers |
Key Cases Cited
- In re Lipitor Antitrust Litig., 855 F.3d 126 (3d Cir.) (state antitrust/consumer claims do not necessarily arise under patent law when they include additional non-patent elements)
- In re Wellbutrin XL Antitrust Litig., 868 F.3d 132 (3d Cir.) (considerations for antitrust standing in reverse-payment cases; "but-for" causation analysis)
- Shady Grove Orthopedic Assocs., P.A. v. Allstate Ins. Co., 559 U.S. 393 (2010) (Rule 23 may preempt conflicting state rules; plurality and concurrence approaches analyzed)
- Dow Chem. Co. v. Exxon Corp., 139 F.3d 1470 (Fed. Cir.) (state unfair-competition claims not preempted when they include additional elements and do not conflict with federal patent objectives)
- Walker Process Equip., Inc. v. Food Mach. & Chem. Corp., 382 U.S. 172 (1965) (fraudulent procurement of a patent can support antitrust liability)
- Klehr v. A.O. Smith Corp., 521 U.S. 179 (1997) (continuing-violation doctrine in antitrust — each overt act restarts limitations period)
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (plausibility standard for pleadings)
- Christianson v. Colt Indus. Operating Corp., 486 U.S. 800 (1988) (scope of federal jurisdiction over patent-related claims)